Stroke Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Stroke treatment encompasses the <strong>full continuum of care</strong> from the moment of brain attack through acute hospitalisation, surgical and interventional procedures, secondary prevention, and long-term neurological management. Stroke is the <strong>second leading cause of death and the leading cause of adult disability</strong> worldwide, with the WHO estimating 15 million strokes annually globally, of which 5 million are fatal and 5 million result in permanent disability.</p><p>Understanding stroke treatment requires distinguishing clearly between <strong>two fundamentally different stroke types</strong>, which require opposite treatment strategies. <strong>Ischemic stroke</strong> (approximately 85% of all strokes) is caused by occlusion of a cerebral artery, depriving downstream brain tissue of oxygen and glucose. Treatment requires rapid restoration of blood flow through thrombolysis or mechanical thrombectomy (in the acute phase), and lifelong antiplatelet or anticoagulation therapy (for secondary prevention). <strong>Hemorrhagic stroke</strong> (approximately 15% of strokes) is caused by rupture of a blood vessel, producing intracranial bleeding. Treatment requires haemostasis, blood pressure control, and in selected cases, surgical intervention. Giving thrombolytics (clot-dissolving drugs) to a hemorrhagic stroke patient is catastrophic — making rapid, accurate diagnosis the <strong>first and most critical step</strong> in stroke care.</p><p>The stakes of secondary prevention are immense. After a first stroke or TIA, the <strong>risk of a second stroke is 20–25% within 5 years</strong>. With optimal secondary prevention — blood pressure control, antiplatelet or anticoagulation therapy, high-intensity statin therapy, smoking cessation, diabetes management, and lifestyle modification — this risk can be reduced by 50–80%. The INTERSTROKE study demonstrated that <strong>10 modifiable risk factors account for 90% of stroke risk</strong> globally, making stroke one of the most preventable of all major diseases.</p><p>Stroke care has been revolutionised over the past three decades. The establishment of <strong>dedicated stroke units</strong> with multidisciplinary teams, the approval of IV thrombolysis (tPA) in 1996, the thrombectomy revolution of 2015, and increasingly powerful secondary prevention medications have transformed outcomes. The challenge now is ensuring equitable, timely access to these evidence-based treatments globally.</p>

<p>Stroke treatment protocols are tailored to the specific stroke subtype, underlying cause, and associated risk factors. Accurate aetiological classification guides both acute management and long-term secondary prevention strategies.</p><h4>Ischemic Stroke Subtypes (TOAST Classification)</h4><ul><li><strong>Cardioembolic Stroke (30-35%):</strong> Caused by cardiac embolism, most commonly from atrial fibrillation (AF), left ventricular thrombus, or valvular disease. Typically produces large territorial infarctions with severe neurological deficits. Requires anticoagulation (DOAC or warfarin) for secondary prevention rather than antiplatelet therapy.</li><li><strong>Large Artery Atherosclerotic Stroke (20-25%):</strong> Atheromatous stenosis or occlusion of major extracranial (carotid, vertebral) or intracranial arteries. Carotid endarterectomy (CEA) or stenting (CAS) indicated for significant ipsilateral carotid stenosis.</li><li><strong>Small Vessel (Lacunar) Stroke (20-25%):</strong> Occlusion of small perforating arteries (lenticulostriate, thalamoperforators, basilar perforators); strongly associated with chronic hypertension and diabetes. Produces small, deep infarcts. Antiplatelet therapy and aggressive BP control are the primary treatments.</li><li><strong>Cryptogenic Stroke (25-30%):</strong> No aetiology identified despite systematic investigation. May be due to occult paroxysmal AF (detected in 10-15% of patients on prolonged cardiac monitoring), patent foramen ovale (PFO), aortic arch atheroma, or non-stenotic atherosclerotic plaque. Embolic stroke of undetermined source (ESUS) is a related category for targeted investigation and treatment.</li></ul><h4>Hemorrhagic Stroke Subtypes</h4><ul><li><strong>Intracerebral Hemorrhage (ICH):</strong> Spontaneous bleeding into brain parenchyma from rupture of small penetrating arteries (hypertensive arteriopathy) or cerebral amyloid angiopathy (CAA). Carries 30-day mortality 40-50%. Anticoagulation-related ICH is an increasing problem.</li><li><strong>Subarachnoid Hemorrhage (SAH):</strong> Arterial bleeding into subarachnoid space; 85% due to ruptured intracranial aneurysm. Presents with sudden-onset severe headache. Emergency neurosurgical or endovascular treatment required.</li></ul><h4>Cerebrovascular Conditions Requiring Stroke Treatment Protocols</h4><ul><li><strong>Transient Ischaemic Attack (TIA):</strong> Same secondary prevention urgency as completed stroke; highest recurrence risk in first 48–72 hours.</li><li><strong>Cerebral Venous Sinus Thrombosis (CVST):</strong> Uncommon cause of stroke, treated with anticoagulation regardless of presence of hemorrhage.</li><li><strong>Carotid Artery Stenosis:</strong> Symptomatic stenosis ≥50% requires urgent CEA or CAS; asymptomatic significant stenosis ≥60-70% may also benefit from revascularisation in selected patients.</li></ul>

<p>Eligibility for different stroke treatments depends on stroke type, timing, severity, aetiology, patient comorbidities, and anatomical factors. A systematic work-up within the stroke unit determines the optimal treatment pathway.</p><h4>Acute Phase Treatment Eligibility</h4><ul><li><strong>IV Thrombolysis (tPA):</strong> Eligible patients: confirmed ischemic stroke within 4.5 hours, NIHSS ≥1, CT head showing no haemorrhage. Contraindications include recent major surgery, significant coagulopathy, extreme blood pressure, prior ICH, and large established infarct. (See Stroke Emergency Treatment page for full eligibility criteria.)</li><li><strong>Mechanical Thrombectomy:</strong> Large vessel occlusion confirmed on CTA, within 6 hours (or up to 24 hours with favourable perfusion imaging); NIHSS ≥6 and small infarct core. Eligible patients should proceed directly to thrombectomy at centres with 24/7 interventional neuroradiology capability.</li></ul><h4>Secondary Prevention Eligibility</h4><ul><li><strong>Antiplatelet Therapy:</strong> All ischemic stroke and TIA patients without AF or prosthetic heart valves. Aspirin initiated at 300 mg within 24 hours of symptom onset (24 hours after tPA if given). Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days for minor ischemic stroke or high-risk TIA (POINT/CHANCE trials).</li><li><strong>Anticoagulation (DOACs / Warfarin):</strong> Cardioembolic stroke due to AF; initiated 4–14 days post-stroke depending on infarct size and haemorrhagic transformation risk. Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) preferred over warfarin for non-valvular AF (lower bleeding risk, better efficacy, no INR monitoring).</li><li><strong>High-Intensity Statin Therapy:</strong> All ischemic stroke and TIA patients, regardless of baseline LDL. Atorvastatin 80 mg daily is the standard; associated with 25% relative risk reduction in recurrent stroke.</li></ul><h4>Surgical Eligibility (Carotid and Cerebrovascular)</h4><ul><li><strong>Carotid Endarterectomy (CEA):</strong> Symptomatic carotid stenosis 50–99% (NASCET criteria); most benefit in 70–99% stenosis; should be performed within 2 weeks of index event (perioperative risk vs benefit most favourable). Requires assessment of perioperative risk by vascular surgeon.</li><li><strong>Carotid Artery Stenting (CAS):</strong> Alternative to CEA for anatomically high-risk surgical candidates, radiation-related stenosis, or restenosis after prior CEA; results equivalent to CEA in experienced centres.</li><li><strong>Hemicraniectomy (Malignant MCA Infarction):</strong> Large hemispheric infarction causing severe cerebral oedema and midline shift; hemicraniectomy within 48 hours reduces mortality from ~80% to ~30% (HAMLET/DECIMAL/DESTINY trials). Requires consent from patient or family regarding functional expectations post-surgery.</li><li><strong>PFO Closure:</strong> Patent foramen ovale closure (transcatheter) in patients aged 18–60 with cryptogenic stroke and confirmed PFO on TOE/bubble echo, after exclusion of other causes (CLOSE, DEFENSE-PFO, REDUCE trials).</li></ul>

<p>Stroke treatment spans the acute, subacute, and chronic phases, each with distinct but interconnected treatment goals. A comprehensive treatment plan addresses both the immediate brain injury and the long-term risk of recurrence.</p><h4>Acute Phase Treatment (0–72 hours)</h4><ul><li><strong>IV Thrombolysis (tPA/tenecteplase):</strong> Rapid dissolution of occluding thrombus; gold-standard acute ischemic stroke treatment within 4.5 hours. (See Stroke Emergency Treatment for full details.)</li><li><strong>Mechanical Thrombectomy:</strong> Catheter-based clot removal for large vessel occlusion; up to 24 hours with perfusion imaging selection.</li><li><strong>Blood Pressure Management:</strong> Ischemic stroke: permissive hypertension (allow up to 220/120 mmHg for first 24 hours unless tPA given, when target <180/105 mmHg). ICH: target SBP <140 mmHg immediately.</li><li><strong>Glucose Management:</strong> Hyperglycaemia (BG >11 mmol/L) significantly worsens ischemic outcomes; insulin infusion to maintain 6–10 mmol/L.</li><li><strong>Temperature Control:</strong> Fever dramatically worsens ischemic injury; treat with paracetamol for temperature >37.5°C; investigate and treat infection.</li></ul><h4>Subacute Phase — Secondary Prevention Medications (initiated during hospitalisation)</h4><ul><li><strong>Antiplatelet Therapy:</strong> Aspirin 300 mg loading, then 75 mg daily (standard maintenance); clopidogrel 75 mg daily (alternative, equivalent efficacy to aspirin for stroke prevention per CAPRIE trial); dual antiplatelet (aspirin + clopidogrel) for 21 days post-minor ischemic stroke or TIA then mono-antiplatelet.</li><li><strong>Anticoagulation for AF:</strong> Apixaban 5 mg bd, rivaroxaban 20 mg od, dabigatran 110/150 mg bd, or edoxaban 60 mg od — all superior to or non-inferior to warfarin with lower ICH risk. Warfarin retained for valvular AF (mitral stenosis, mechanical prosthetic valve) with target INR 2.5–3.5.</li><li><strong>High-Intensity Statins:</strong> Atorvastatin 40–80 mg daily; reduces LDL by 40–50%. The SPARCL trial (atorvastatin 80 mg) demonstrated a 16% relative risk reduction in recurrent stroke vs placebo. LDL target <1.8 mmol/L (<70 mg/dL) for all stroke patients.</li><li><strong>Antihypertensive Therapy:</strong> Long-term target <130/80 mmHg (2022 AHA/ACC guidelines). ACE inhibitors + thiazide diuretic combination has strong evidence (PROGRESS trial: reduced stroke recurrence by 43%).</li></ul><h4>Surgical and Interventional Treatments</h4><ul><li><strong>Carotid Endarterectomy (CEA):</strong> Open surgical removal of atheromatous plaque from the carotid artery bifurcation; general or local anaesthesia; performed within 2 weeks of TIA/minor stroke for maximum benefit.</li><li><strong>Carotid Artery Stenting (CAS):</strong> Percutaneous deployment of self-expanding stent; embolic protection device used during procedure; equally effective as CEA in experienced centres for most patients.</li><li><strong>Decompressive Hemicraniectomy:</strong> Removal of a large skull segment to allow the swollen brain to expand; lifesaving in malignant MCA infarction.</li><li><strong>Aneurysm Treatment (SAH):</strong> Endovascular coiling (first-line in most centres; ISAT trial) or surgical clipping; prevents re-haemorrhage. Vasospasm prophylaxis with nimodipine 60 mg q4h for 21 days.</li><li><strong>PFO Closure:</strong> Transcatheter closure using Amplatzer or Gore Cardioform devices in selected cryptogenic stroke patients.</li></ul>

<p>The evidence supporting the various components of stroke treatment is among the most compelling in cardiovascular medicine, with multiple large randomised controlled trials and meta-analyses demonstrating substantial reductions in stroke recurrence, disability, and mortality.</p><h4>Acute Treatment Benefits</h4><ul><li><strong>IV Thrombolysis:</strong> Reduces the proportion of patients with major disability or death by 30% (NNT ≈ 6). In the 0–90 minute window, NNT ≈ 4. Benefits outweigh the 6-8% risk of symptomatic intracranial haemorrhage for most eligible patients.</li><li><strong>Mechanical Thrombectomy:</strong> HERMES meta-analysis: 46% relative reduction in severe disability, 20% absolute increase in functional independence (NNT ≈ 2–5 depending on patient selection). The most effective acute intervention in modern stroke medicine.</li><li><strong>Stroke Unit Care:</strong> Reduces death or dependency by 18% compared to general ward care — equivalent in magnitude to the benefit from thrombolysis. Every stroke patient, regardless of severity, should be managed in a dedicated stroke unit.</li></ul><h4>Secondary Prevention Benefits</h4><ul><li><strong>Anticoagulation for AF:</strong> DOACs reduce annual stroke risk from approximately 4-6% (untreated AF) to <1%; 65-70% relative risk reduction. For patients who cannot take anticoagulants, left atrial appendage closure (Watchman device) provides an alternative.</li><li><strong>Antihypertensive Treatment:</strong> 10 mmHg reduction in SBP reduces stroke risk by approximately 30-40%; reducing SBP from 160 to 130 mmHg halves the stroke risk. PROGRESS trial (perindopril + indapamide): 43% relative reduction in recurrent stroke.</li><li><strong>Statin Therapy:</strong> SPARCL trial: atorvastatin 80 mg reduced recurrent stroke by 16% vs placebo. Pleiotropic effects including anti-inflammatory and plaque-stabilising benefits beyond LDL reduction.</li><li><strong>Antiplatelet Therapy:</strong> Aspirin reduces relative risk of recurrent ischemic stroke by approximately 25%; clopidogrel provides equivalent benefit with possibly superior GI tolerability.</li></ul><h4>Surgical Benefits</h4><ul><li><strong>Carotid Endarterectomy:</strong> NASCET trial: CEA reduces 5-year ipsilateral stroke risk from 26% to 9% in symptomatic ≥70% stenosis (absolute risk reduction 17%); 15-year absolute stroke risk reduction maintained. For 50-69% stenosis: 5-year ARR approximately 7%.</li><li><strong>Hemicraniectomy:</strong> Reduces mortality from approximately 80% to 30% in malignant MCA infarction, though many survivors have moderate-to-severe disability.</li><li><strong>PFO Closure:</strong> CLOSE trial: PFO closure + antiplatelet therapy vs antiplatelet alone — no recurrent stroke at 5 years in closure group vs 6% in antiplatelet-only group.</li></ul><p>The combined implementation of all evidence-based secondary prevention measures can reduce stroke recurrence risk by <strong>50–80% compared to no treatment</strong>. This makes post-stroke secondary prevention one of the highest-value medical interventions available.</p>

<p>All stroke treatments carry potential risks that must be weighed against the substantial benefits of preventing recurrent stroke and reducing disability. The clinical team is trained to minimise risks through careful patient selection, monitoring, and prompt management of complications.</p><h4>Risks of Acute Interventions</h4><ul><li><strong>tPA Haemorrhagic Transformation:</strong> Symptomatic ICH in 6-8%; managed with cessation of infusion, haematological reversal (cryoprecipitate, TXA), and neurosurgical review if indicated.</li><li><strong>Thrombectomy Complications:</strong> Groin haematoma, vessel injury, distal embolisation, reperfusion haemorrhage (4-9%), and — rarely — arterial perforation. Risk-benefit analysis overwhelmingly favours intervention in eligible LVO patients.</li></ul><h4>Risks of Secondary Prevention Medications</h4><ul><li><strong>Antiplatelet Agents — Bleeding:</strong> Aspirin increases annual GI bleeding risk by approximately 0.3%. GI protection with PPI (omeprazole) recommended for patients at high GI bleeding risk. Dual antiplatelet therapy carries higher bleeding risk than monotherapy beyond 21-30 days.</li><li><strong>DOACs — Systemic Bleeding:</strong> Annual major bleeding rates 2-3%; ICH rates significantly lower than warfarin (approximately 50% risk reduction). Specific reversal agents available (idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors).</li><li><strong>Warfarin — Bleeding and Interaction Risks:</strong> Narrow therapeutic window; multiple drug and food interactions require close INR monitoring; ICH risk higher than DOACs. Retained for valvular AF and mechanical heart valves.</li><li><strong>Statins — Myopathy and Hepatotoxicity:</strong> Myalgia common (5-10%); clinically significant myopathy or rhabdomyolysis rare (<0.1%). Transient LFT elevation occurs in 1-3%; clinical hepatotoxicity rare. Statin intolerance managed by dose reduction, alternate-day dosing, or switching to different statin.</li><li><strong>Antihypertensives — Hypotension and Falls:</strong> Over-aggressive BP lowering — particularly in older adults with orthostatic hypotension — can cause falls, syncope, and cerebral hypoperfusion. Gradual titration and morning BP monitoring essential.</li></ul><h4>Surgical Risks</h4><ul><li><strong>Carotid Endarterectomy / CAS:</strong> Combined perioperative stroke and death risk 2-6% (varies by stenosis degree, centre experience, and patient comorbidities). Cranial nerve injury (particularly marginal mandibular branch of facial nerve) in 5-7% of CEA, usually temporary. Hyperperfusion syndrome (<1%) after CEA in severely stenosed vessels.</li><li><strong>Hemicraniectomy:</strong> Surgical site infection, wound dehiscence, CSF leak, and the psychosocial challenge of significant but functional survival for many patients and families.</li></ul><p>All risks should be discussed explicitly with the patient and family as part of informed consent. The treating stroke team has the expertise to contextualise these risks against the far greater risk of untreated stroke recurrence.</p>

<p>Structured post-stroke follow-up is essential to optimise secondary prevention, monitor for recurrence, manage ongoing deficits, address psychological sequelae, and support return to full life participation. National stroke guidelines recommend a systematic follow-up schedule for all survivors.</p><h4>Early Post-Discharge Phase (0–4 weeks)</h4><ul><li><strong>2–4 week neurology outpatient review:</strong> Clinical neurological examination; medication review (tolerability, adherence, dosing); neuroimaging review if new neurological symptoms; secondary prevention optimisation.</li><li><strong>Cardiac workup:</strong> Echocardiogram (within 4 weeks) to assess LV function, identify LV thrombus, valvular disease, or PFO; prolonged Holter monitor (14-30 days) or implantable loop recorder for cryptogenic stroke to detect paroxysmal AF.</li><li><strong>Carotid imaging:</strong> If not completed during acute admission; carotid duplex ultrasound or CTA to identify significant carotid stenosis requiring CEA/CAS.</li><li><strong>Fasting lipid panel:</strong> LDL target <1.8 mmol/L (<70 mg/dL) confirmed; statin dose optimised accordingly.</li></ul><h4>Medium-Term Follow-Up (1–12 months)</h4><ul><li><strong>3-month neurology review:</strong> mRS and Barthel Index reassessment; MoCA cognitive screening; PHQ-9 depression screening; rehabilitation progress review; driving assessment eligibility discussion.</li><li><strong>6-month review:</strong> Comprehensive secondary prevention assessment; blood pressure, LDL, HbA1c, renal function (particularly if on ACEi/ARB); anticoagulation management (INR for warfarin, renal function for DOACs); lifestyle adherence support.</li><li><strong>Vocational rehabilitation:</strong> Return-to-work planning for working-age survivors; workplace accommodation assessments; driving fitness assessment at 3–6 months.</li></ul><h4>Long-Term Annual Review</h4><ul><li><strong>Annual stroke health review:</strong> Structured annual assessment of secondary prevention targets; cognitive screening for vascular cognitive impairment; functional independence review; psychological wellbeing assessment; medication reconciliation.</li><li><strong>Ongoing anticoagulation monitoring:</strong> For warfarin patients, regular INR (target 2.0–3.0 for non-valvular AF); for DOAC patients, annual renal function (eGFR determines dosing, particularly for dabigatran); for patients with mechanical valves, lifelong INR monitoring.</li><li><strong>Lifestyle support:</strong> Ongoing support for smoking cessation, exercise (150 min/week moderate aerobic), Mediterranean diet adherence, alcohol moderation, and weight management.</li></ul><p>Patients should be educated to recognise the signs of stroke recurrence (FAST symptoms) and seek emergency care immediately. <strong>Never ignore transient neurological symptoms</strong> — TIA requires the same urgency as completed stroke.</p>

<p>Stroke is one of the most economically costly medical conditions globally, with costs arising across the acute treatment episode, rehabilitation, long-term care, and lifetime secondary prevention. Understanding costs helps patients and healthcare systems plan appropriately.</p><h4>Acute Stroke Treatment Costs (United States)</h4><ul><li><strong>Acute hospitalisation:</strong> Average total hospitalisation cost for acute ischemic stroke with thrombolysis: $35,000–$80,000; with thrombectomy: $60,000–$130,000; based on severity, length of stay, and complications. In-ICU care adds $4,000–$8,000/day.</li><li><strong>Diagnostic imaging:</strong> Emergency CT/CTA: $500–$3,000; MRI brain: $1,500–$5,000; CT perfusion imaging: $1,000–$4,000; diagnostic angiography: $3,000–$8,000.</li><li><strong>Cardiac workup:</strong> Echocardiogram $300–$1,500; extended Holter $200–$800; implantable loop recorder $5,000–$10,000 (device + implant).</li></ul><h4>Surgical Treatment Costs</h4><ul><li><strong>Carotid Endarterectomy (CEA) — United States:</strong> $10,000–$30,000 total episode of care; includes surgeon, anaesthetist, hospital facility, and perioperative monitoring.</li><li><strong>Carotid Artery Stenting (CAS):</strong> $15,000–$35,000 in the US; stent and embolic protection device costs $3,000–$6,000.</li><li><strong>PFO Closure:</strong> $15,000–$30,000 in the US; closure devices (Amplatzer, Gore) $4,000–$7,000.</li></ul><h4>Secondary Prevention Medication Costs (Monthly)</h4><ul><li><strong>Generic aspirin 75 mg:</strong> <$1/month — the most cost-effective medication in stroke prevention.</li><li><strong>Generic clopidogrel:</strong> $5–$20/month in the US; $2–$10/month in India.</li><li><strong>DOACs (apixaban, rivaroxaban):</strong> $400–$600/month in the US without insurance; $30–$80/month in India and Southeast Asia; significantly reduced with insurance.</li><li><strong>Generic atorvastatin:</strong> $5–$20/month (US discount programmes); $3–$10/month in India.</li><li><strong>ACE inhibitor/ARB + thiazide combination:</strong> Generic options $5–$30/month.</li></ul><h4>International Cost Comparisons</h4><ul><li><strong>India:</strong> Complete stroke evaluation and CEA at private tertiary centres $5,000–$15,000 including hospitalisation; full secondary prevention workup $500–$2,000. Ongoing medications 80-90% cheaper than US.</li><li><strong>Thailand / Malaysia / Turkey:</strong> CEA or CAS $6,000–$15,000 at JCI-accredited centres; acute stroke hospitalisation $5,000–$20,000.</li><li><strong>United Kingdom (NHS):</strong> Fully publicly funded; no direct costs to patients; NHS acute stroke admission average £6,000–£12,000 total cost.</li></ul>

<p>While no evidence-based alternative medicine approach can replace antiplatelet therapy, anticoagulation, statins, or carotid surgery for stroke treatment, lifestyle modification is <strong>quantifiably the most powerful stroke prevention tool</strong> and a critical adjunct to pharmacological secondary prevention. The INTERSTROKE study identified 10 modifiable risk factors accounting for 90% of all stroke risk worldwide — all addressable without medications.</p><h4>Lifestyle Modifications with Strong Evidence</h4><ul><li><strong>Blood Pressure Control Through Diet:</strong> DASH diet (Dietary Approaches to Stop Hypertension) reduces SBP by 8–14 mmHg — equivalent to one antihypertensive drug. Sodium restriction (<2g/day) reduces SBP by 4–5 mmHg. Combined with weight loss, these effects are substantial.</li><li><strong>Aerobic Exercise:</strong> 150 minutes/week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming) reduces stroke risk by 25–30%, improves BP, HDL cholesterol, insulin sensitivity, and BMI simultaneously.</li><li><strong>Smoking Cessation:</strong> Smoking doubles stroke risk; cessation reduces stroke risk to non-smoker levels within 5 years. Combined with nicotine replacement therapy and behavioural counselling, 6-month cessation rates of 25-35% are achievable.</li><li><strong>Alcohol Moderation:</strong> Heavy alcohol consumption is a significant ischemic and hemorrhagic stroke risk factor; reducing to <14 units/week (women) or <21 units/week (men) reduces risk. AF risk is also alcohol-dose-dependent.</li><li><strong>Mediterranean Diet:</strong> PREDIMED trial: Mediterranean diet supplemented with olive oil or nuts reduced cardiovascular events (including stroke) by 30% vs low-fat diet control. Rich in polyphenols, omega-3 fatty acids, fibre, and antioxidants.</li><li><strong>Weight Management:</strong> Each 5 kg/m2 increase in BMI is associated with approximately 40% increase in ischemic stroke risk. Weight loss of 5-10% reduces BP, blood glucose, and AF risk.</li></ul><h4>Complementary Approaches as Adjuncts</h4><ul><li><strong>Omega-3 Fatty Acids:</strong> High-dose EPA (icosapentaenoic acid) — as in REDUCE-IT trial (icosapentaenoic acid 4g/day) — reduced composite cardiovascular events by 25% in statin-treated patients with elevated triglycerides. Now recommended as an add-on in relevant patients.</li><li><strong>Acupuncture:</strong> Used widely in Asia for post-stroke symptom management and as adjunct rehabilitation; evidence for direct stroke prevention is limited, but potential role in blood pressure modulation and stress reduction.</li><li><strong>Stress Reduction:</strong> Chronic psychological stress is an independent stroke risk factor via multiple pathways (BP elevation, AF triggering, behavioural risk factor clustering). Mindfulness-based stress reduction and CBT programs, as adjuncts to conventional treatment, support comprehensive secondary prevention.</li></ul><p><strong>Critical caveat:</strong> Complementary approaches must <em>not</em> substitute for evidence-based stroke treatments. Patients should inform their healthcare team of all supplements and alternative therapies used, as some (e.g., St John's Wort, fish oil at high dose, Ginkgo biloba) have interactions with antiplatelet or anticoagulation therapy.</p>